# US 2025/0375457 A1 · Topical pharmaceutical compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375457 A1
- Document ID: US20250375457A1
- Status: Published application
- Kind: A1
- Application number: 19/241,890
- Filed: 2025-06-18
- Published: 2025-12-11
- Earliest claimed: 2022-12-19
- Assignees: Shenzhen Pharmacin Co., Ltd.
- Applicants: Shenzhen Pharmacin Co., Ltd.
- Inventors: Shun CHEN; Zeren WANG; Peter FARINA; Lian WANG; Xiaoyan ZHOU; Jing SHAO
- Web page: https://patentgrep.com/patent/US20250375457A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating a skin-related disease or disorder (such as melasma). Also provided are pharmaceutical compositions of midostaurin or a pharmaceutically acceptable salt thereof formulated for topical administration. Further described are methods for preparing such topical pharmaceutical compositions and methods of using the same for treating a subject.

## Claims

### Claim 1

A method of treating a skin-related disease or disorder, the method comprising topically applying a multi-targeting protein kinase inhibitor or a salt thereof to a skin of a subject, wherein the skin is associated with a skin-related disease or disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the skin-related disease or disorder is skin pigmentation disorder.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the multi-targeting protein kinase inhibitor is midostaurin or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has a skin hyperpigmentation condition.

### Claim 7 (depends on 6)

The method of claim 6, wherein the skin hyperpigmentation condition comprises a sunspot or an age spot.

### Claim 8 (depends on 6)

The method of claim 6, wherein the skin hyperpigmentation condition comprises melasma, post-inflammatory hyperpigmentation, posttraumatic pigmentation, discoid lupus erythematous, freckles, plaques gravidarum, nevus of Ota, or aging pigmentation.

### Claim 9 (depends on 5)

The method of claim 5 wherein the method skin-related disease or disorder is melasma.

### Claim 10 (depends on 9)

The method of claim 9, wherein the skin is on the subject's face.

### Claim 11 (depends on 9)

The method of claim 9, wherein the melasma is chloasma.

### Claim 12 (depends on 11)

The method of claim 11, wherein the melasma is caused by or exacerbated by one or more of: birth control pills, pregnancy, hormone therapy, stress, thyroid disease, sunlight exposure, inflammation, familial predisposition, or free radicals.

### Claim 13 (depends on 1)

The method of claim 1, wherein the treating comprises reducing the size of abnormal skin pigmentation, reducing the intensity of abnormal skin pigmentation, and/or eliminating the abnormal skin pigmentation associated with the melasma.

### Claim 14 (depends on 1)

The method of claim 1, wherein the treating comprises reducing melanin amount in an area of the skin by at least 25% compared to a similar area of skin in the same subject without the treatment.

### Claim 15 (depends on 1)

The method of claim 1, wherein the treating comprises reducing melanin amount in an area of the skin by at least 1.0 according to Melanin Distribution Score compared to a similar area of skin in the same subject without the treatment.

### Claim 16 (depends on 1)

The method of claim 1, wherein the treating comprises reducing melanin amount in an area of the skin by at least 1.0 according to Fontana-Masson staining scoring standard compared to a similar area of skin in the same subject without the treatment.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method does not create moderate or severe skin irritation in the subject.

### Claim 18 (depends on 1)

The method of claim 1, comprising topically applying a pharmaceutical composition, wherein the pharmaceutical composition comprises midostaurin or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein a therapeutically effective amount of the multi-targeting protein kinase inhibitor or a salt thereof is a dose that is 80% less than that for hydroquinone.

### Claim 20

A topical pharmaceutical composition comprising
a) a multi-targeting protein kinase inhibitor (optionally midostaurin) or a pharmaceutically acceptable salt thereof in an amount of 0.001% to about 20% wt;
b) a carrier vehicle; and
c) an excipient;
wherein the topical pharmaceutical composition is formulated for topical administration.

### Claim at position 21

21-31. (canceled)

### Claim 32 (depends on 20)

The topical pharmaceutical composition of claim 20, wherein the excipient comprises a surfactant, a penetration enhancer, an antioxidant, a sun-screening agent, a viscosity modifier, a pH stabilizer, or a moisturizer, or any combination thereof.

### Claim at position 23

33-64. (canceled)

### Claim 65 (depends on 20)

The topical pharmaceutical composition of claim 20, wherein the topical pharmaceutical composition is in a form selected from an ointment, a gel, a cream, a lotion, a solution, an emulsion, a paste, a patch, a wipe, a swab, and a pad.

### Claim at position 25

66-72. (canceled)

### Claim 73 (depends on 20)

The topical pharmaceutical composition of claim 20, wherein the topical pharmaceutical composition comprises;
midostaurin or a pharmaceutically acceptable salt thereof in an amount of about 0.01% to about 5% wt;
a carrier vehicle in an amount of about 30% to about 70% wt;
a surfactant in an amount of about 5% to about 50% wt;
optionally a moisturizer in an amount of about 5% to about 30% wt;
optionally a penetration enhancer in an amount of about 1% to about 40% wt;
optionally a viscosity modifier in an amount of about 0.01% to about 5% wt; and
an antioxidant in an amount of about 0.001% to 5% wt.

### Claim at position 27

74-92. (canceled)

### Claim 93

A method of reducing tyrosinase activity, the method comprising topically applying a topical pharmaceutical composition to a skin of a subject in need thereof, wherein the topical pharmaceutical composition comprises midostaurin or a pharmaceutically acceptable salt thereof.

### Claim at position 29

94-96. (canceled)

### Claim 97 (depends on 20)

A kit comprising a package enclosing the topical pharmaceutical composition of claim 20.

### Claim 98 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied at a dose from about 0.01 mg to about 20 mg per day.

### Claim 99 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied at a dose from about 0.1 mg to about 5 mg per day.

### Claim 100 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied at a dose of about 0.1 mg per day, about 0.2 mg per day, about 0.3 mg per day, about 0.4 mg per day, about 0.5 mg per day, about 0.6 mg per day, about 0.7 mg per day, about 0.8 mg per day, about 0.9 mg per day, about 1 mg per day, about 1.5 mg per day, about 2 mg per day, about 2.5 mg per day, about 3 mg per day, about 3.5 mg per day, about 4 mg per day, about 4.5 mg per day, or about 5 mg per day.

### Claim 101 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied at a dose that is 80% less than that for 2% hydroquinone cream, 70% less than that for 2% hydroquinone cream, or 50% less than that for 2% hydroquinone cream.

### Claim 102 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied once a day.

### Claim 103 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied twice a day.

### Claim 104 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is applied once a day or twice a day for at least one week.
